Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy

Justin Loke, Marlen Metzner, Rebecca Boucher, Aimee Jackson, Louise Hopkins, Jiri Pavlu, Eleni Tholouli, Mark Drummond, Andy Peniket, Rebecca Bishop, Sonia Fox, Paresh Vyas, Charles Craddock

Research output: Contribution to journal › Article › peer-review

64 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences